found that autophagy is an important mechanism of CRPC resistance to AR inhibitors (such as bicalutamide and enzalutamide), and blocking autophagy significantly reduced the survival of PCa cells in vitro and in vivo, suggesting the great potential of autophagy inhibitors in the treatment of patients with CRPC (26). This evidence concerns the gene AR and posterior cortical atrophy.